Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
Earnings Data
Report Date
May 09, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.15Last Year’s EPS
-0.38Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 07, 2025
|% Change Since: 0.00%
|Next Earnings Date:May 09, 2025
Earnings Call Sentiment|Neutral
The earnings call presents significant achievements, particularly the FDA approval of ORLYNVAH and its market potential, coupled with improved financial performance. However, the uncertainty in strategic partnerships and financial obligations create notable challenges.Company Guidance
During the Iterum Therapeutics fourth quarter and full year 2024 financial results call, the company outlined its strategic plans and financial metrics. Iterum reported total operating expenses of $3.7 million for Q4 and $18.7 million for the full year 2024, a decrease from $11.4 million and $47.5 million in 2023, primarily due to the completion of the REASSURE trial. The net loss on a GAAP basis was $6.6 million for Q4 and $24.8 million for the year, while on a non-GAAP basis, it was $3.1 million and $17.6 million, respectively. The company's cash and cash equivalents stood at $24.1 million at year-end, expected to fund operations into the second half of 2025. Iterum aims to maximize the value of ORLYNVAH, its recently FDA-approved product, through potential strategic transactions or direct commercialization, highlighting its unique position in the US market for treating uncomplicated urinary tract infections.FDA Approval of ORLYNVAH
In October 2024, Iterum received FDA approval for ORLYNVAH, the first and only approved oral penem in the United States for the treatment of uncomplicated urinary tract infections.
Market Potential and Exclusivity
ORLYNVAH has a strong market potential in the US, with an estimated 40 million prescriptions annually for uncomplicated urinary tract infections. It also has 10 years of market exclusivity under the GAIN Act and patent protection into 2039.
Financial Performance Improvement
The non-GAAP net loss decreased by $7.6 million for Q4 2024 and $26.2 million for the full year compared to 2023, primarily due to lower R&D expenses.
---
ITRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ITRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 07, 2025 | $1.49 | $1.43 | -4.03% |
| Nov 14, 2024 | $1.43 | $1.36 | -4.90% |
| Aug 14, 2024 | $1.17 | $1.21 | +3.42% |
| May 13, 2024 | $1.55 | $1.52 | -1.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Iterum Therapeutics Plc (ITRM) report earnings?
Iterum Therapeutics Plc (ITRM) is schdueled to report earning on May 09, 2025, TBA Not Confirmed.
What is Iterum Therapeutics Plc (ITRM) earnings time?
Iterum Therapeutics Plc (ITRM) earnings time is at May 09, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ITRM EPS forecast?
ITRM EPS forecast for the fiscal quarter 2025 (Q1) is -0.15.
---